Treating Diabetes Mellitus: Pharmacophore Based Designing of Potential Drugs from Gymnema sylvestre against Insulin Receptor Protein

Table 2

Ligand properties of Gymnema sylvestre compounds.

Ligand properties	Conduritol A	Conduritol B tetraacetate	Conduritol C cis-epoxide	Conduritol D	Conduritol E tetranitro	GS4	Gymnemic acid I	Gymnemic acid II	Gymnemoside A	Gymnemoside B
Docking energy (Kcal/mol)	−5.2	−5.7	−5.3	−5.6	−8.0	−8.7	−10.8	−9.4	−10.9	−10.4
Molecular weight (g/mol)	146.1412	314.28792	162.1406	146.1412	326.1314	714.78	806.98	682.838	806.9757	806.9757
Number of H donor	4	2	4	4	2	14	7	9	7	7
Number of H acceptor	4	8	5	2	12	21	14	12	14	14
Log	−1.958	−0.295	−0.237	−0.326	−4.065	−1.133	−1.133	−1.133	−5.38	−5.38
Log	−1.63	0.31	−0.205	−1.631	−2.829	−5.169	−5.169	−5.169	−2.976	−2.976
TPSA	80.92	105.2	93.45	80.92	220.2	401	401	401	229.7	229.7
Drug likeness	−0.05	−0.02	−0.218	−0.495	−2.168	−7.992	−7.992	−7.992	−6.524	−6.619
Oral bioavailability	30%–70%	30%–70%	30%–70%	30%–70%	More than 70%	More than 70%	30%–70%	More than 70%	More than 70%	More than 70%